Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

A method of increasing CBN content in a Cannabinoid oil includes processing plant parts from one or more cannabis plants to create processed plant parts, extracting a Cannabinoid oil from the processed plant parts, and refining the Cannabinoid oil to increase CBN content.

A method of extracting active ingredients in mushrooms includes following steps: crushing a mushroom to obtain a crude mushroom crush; mixing the crude mushroom crush with deionized water to obtain a crude crush mixture; adding the crude crush mixture into a subcritical fluid extractor and extracting the crude crush mixture to obtain a crude mushroom extract; centrifuging the crude mushroom extract to harvest a first supernatant and a mushroom residue; mixing the mushroom residue with deionized water and a cellulase enzyme to obtain a reaction mixture; adding the reaction mixture into a high-pressure hydrolysis reactor and extracting the reaction mixture to obtain a hydrolysate; centrifuging the hydrolysate to obtain a second supernatant; and combining the first supernatant and the second supernatant, and then concentrating the combined first and second supernatants to obtain a mushroom extraction solution.

A method of producing a mechanically extracted pseudo-polymorphic Cannabis extract by compressing a Cannabis substance between a heat resistant material and placing the sandwiched Cannabis substance on a press plate, pressing the Cannabis substance at a predetermined pressure for a predetermined time with the press at a temperature, releasing the press, heating the press plates to a predetermined temperature, pressing the Cannabis substance at a predetermined pressure for a predetermined time while the press plates are being heated to the predetermined temperature, collecting an extract expressed from the Cannabis substance, and storing the extract.

An antibacterial antiviral pharmaceutical composition, comprising the following raw materials in parts by weight: 4-14 parts of Herba pogostemonis, 9-28 parts of Rhizoma atractylodis, 5-18 parts of Herba elshoitziae, 11-33 parts of Folium artemisiae argyi, 0.1-3 parts of Flos caryophylli, and 2-10 parts of Herba menthae, and further comprising natural borneol and pharmaceutical adjuvants. The pharmaceutical composition can be prepared into medicinal volatile oil. The pharmaceutical composition and the volatile oil thereof can be used for resisting bacteria and viruses, clearing heat, reducing fever and/or treating respiratory diseases, and can be applied to the preparation of medicines for resisting SARS-CoV-2.

A method for producing full spectrum hemp extract comprising extracting substances from cannabis-based green material that are soluble in an extraction solvent and collecting an extract that includes the extraction solvent distilling at least a portion of the extraction solvent which results in a concentrate that is not distilled off, removing at least a portion of water soluble substances from the concentrate by partitioning the at least a portion of water soluble substances into an aqueous phase and a remainder of substances from the concentrate into a partitioned concentrate, heating the partitioned concentrate to evaporate the nonpolar solvent and to yield a crude oil, degassing the crude oil by heating it which results in a degassed crude oil, performing a first pass distillation at about 150° C. and collecting a first residue, performing a second and third pass distillation at about 170° C. and about 185° C., and collecting a distillate from same.

The present invention discloses sporoderm-removed Ganoderma lucidum spore powder, granule and a preparation method thereof. The sporoderm-removed Ganoderma lucidum spore powder and granule is obtained from sporoderm-disrupted Ganoderma lucidum spore powder through extraction, centrifugation, sporoderm removal, concentration, drying, and pulverization; and in the sporoderm-removed Ganoderma lucidum spore powder and granule, the content of polysaccharides is 10-20 g/100 g, and the content of total triterpenes is 4-10 g/100 g. The present invention has beneficial effects of enhancing immunity and having an auxiliary protection function against radiation hazards. The content of active components is increased by processing the sporoderm-disrupted Ganoderma lucidum spore powder through a special process, such that the human body can more effectively absorb the nutritional components contained in the Ganoderma lucidum spores, and thus the Ganoderma lucidum spore powder gives play to its efficacy better while it is convenient to carry and take the Ganoderma lucidum spore powder.

The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.

The Agastache rugosa extract or the isoagastachoside or crude polysaccharide fraction included in the extract according to the present invention can be prepared based on plants being domestically cultivated, and thus is advantageous in terms of time and cost, and can effectively inhibit the differentiation, growth, and bone resorption functions of osteoclast progenitor cells, thus increasing bone density and the like, and accordingly, can be effectively used for the prevention, amelioration, or treatment of diseases related to bone loss caused by differentiation into osteoclasts or excessive activity of osteoclasts. In addition, the active ingredient, which is a plant-derived natural substance, is safe due to fewer side effects on the human body compared to chemical drugs, and inhibits osteoclast progenitor cells independently of estrogen, and thus can be widely used in osteoporosis occurring due to various causes other than menopause.

A composition is formulated in a therapeutic amount to maintain and promote hair health and growth in a human in need thereof. The composition may comprise a shelf stable, supercritical CO.sub.2 fluid extracted, enhanced lipidosterolic extract of Serenoa repens (LSESr). The enhanced LSESr may have a ratio of free fatty acids to total fatty acids that is greater than about 80.0% and an enrichment of lauric, myristic, oleic and linoleic acids as free fatty acids to total free fatty acids that is greater than about 82.0%. An enrichment of linoleic and linolenic acids together may be greater than about 3.7%.